157060-87-2Relevant academic research and scientific papers
QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY
-
Paragraph 0199; 0200, (2016/02/29)
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
-
Page/Page column 21, (2009/04/24)
The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes (specifically, the alpha7 nAChR subtype). The present invention also relates to methods for treating a wide variety of conditions and disorders, particularly those associated with dysfunction of the central and autonomic nervous systems.
POLYCYCLIC DIAZODIOXIDE-BASED BCL-2 PROTEIN ANTAGONIST
-
Page 35-37, (2008/06/13)
Compounds of Formula 8 are provided: A and B are each independently selected from the group consisting of -NO-, -SO-, and - NR9-. C is a single bond or a double bond. D is selected from the group consisting of single bond, E is selected from th
Design, Synthesis, and Study of 9-Substituted Ellipticine and 2-Methylellipticinium Analogues as Potential CNS-Selective Antitumor Agents
Anderson, Wayne K.,Gopalsamy, Ariamala,Reddy, Peech S.
, p. 1955 - 1963 (2007/10/02)
N,N-Dimethylformamide (DMF) dineopentyl acetal-mediated O-alkylations of 9-hydroxyellipticine gave 9-ethoxy-, 9-(1-methylethoxy)-, and 9-(1,1-dimethylethoxy)ellipticine (3a, 4a, and 5a, respectively). Methylation of the O-alkylellipticines gave the corresponding N-methylpyridinium iodides (3b, 4b, and 5b). The iodides were converted to the acetates (3c, 4c, and 5c) by ion-exchange resin. Attempts to prepare 9-(2,2,2-trifluoroethoxy)ellipticine (6a) using the DMF acetal gave 10-(2,2,2-trifluoroethoxy)-9-hydroxyellipticine (8a). 9-(2,2,2-Trifluoroethoxy)- and 9-phenoxyellipticine (6a and 7a, respectively) were prepared by total synthesis. The ellipticines and N-methylellipticinium derivatives were evaluated for in vitro antitumor activity against a panel of human tumors. 2-Methyl-9-(1,1-dimethylethoxy)ellipticinium acetate (5c) was inactive, but all of the other compounds exhibited significant antitumor activity. The ellipticines showed no significant subpanel specificity; however, the N-methylellipticinium compounds tested did exhibit specificity for the CNS tumor subpanel.
